Accord Healthcare Adds Generic Drug Approved for the Treatment of Relapsing MS
Accord Healthcare, a leading generic pharmaceutical company, has added Teriflunomide to its portfolio of oral medications for the treatment of multiple sclerosis (MS). The drug is formulated as a film-coated tablet. Accord’s Teriflunomide is therapeutically equivalent to Sanofi Genzyme’s Aubagio® and is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. Accord’s product is offered in a 14mg tablet and a 7mg tablet and is currently available to ship.
Teriflunomide is approved by the FDA for use as an immunomodulatory agent in patients 18 and older to decrease the frequency and severity of disease flare-ups, called relapses, to prevent new symptoms or a worsening of old symptoms related to the disease’s neurologic impact.
“We’re proud to add Teriflunomide to our portfolio. This is an important oral therapy for the millions of patients living with relapsing MS,” said Accord Healthcare U.S. Vice President of Sales Jim Brown. “Generic medicine allows broad access to effective therapy, to help improve disease course and potentially slow progression of MS.”
Important Safety Information: Teriflunomide can cause serious liver problems, including liver failure that may be life-threatening or require a liver transplant.2 The risk of developing serious liver problems may be higher for those with liver problems or who take other medicines that also affect the liver. Teriflunomide is contraindicated for use in pregnant women and in females of reproductive potential who are not using effective contraception because of the potential for fetal harm.2 Teriflunomide may stay in the blood for up to two years after taking it.
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more